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Summary This study was undertaken to examine the relationship between circulating
matrix metalloproteinase (MMP-9) and tissue inhibitor of matrix metalloproteinase
(TIMP-1) in our patients with either advanced small-cell lung cancer (SCLC) or non-
small-cell lung cancer (NSCLC) prior to treatment. Thirty-one male and female
patients with either stage III or IV NSCLC and 17 with either stage III or IV SCLC were
compared to 117 age matched non-smoking controls of both sexes. Prior to any
treatment of the patient, a baseline serum sample was obtained from each of the
patients for the determination of circulating MMP-9 and TIMP-1 by ELISA. The results
indicate that both MMP-9 and TIMP-1 are elevated in the serum of lung cancer
patients when compared to the controls. This observation was true for both SCLC and
NSCLC. However, the mean values for both MMP-9 and TIMP-1 in the two tumors were
not different from each other. The natural physiological relationship between MMP-9
and the inhibitor TIMP-1 was lost in both SCLC and NSCLC, indicative of abnormal
alterations by the tumor. The data from this study suggests that advanced lung cancer
does alter the normal circulatory pattern of MMP-9 and TIMP-1. This could aid in the
processes of tumor invasion and/or metastasis.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
It has been well established that the breakdown
process involving the extracellular matrix (ECM),
surrounding various cells in the body is controlled in
large part by the interplay of numerous stimuli.
One major stimulus of this process in part regulated
by the urokinase plasminogen activator (uPA) is the
collection of proteolytic enzymes known as the
metalloproteinases. These metalloproteinases tar-
get the various substrates of the ECM, causing their
dissolution. These proteolytic enzymes target
among others the collagens, gelatin, elastin, fibrin,
and proteoglycans that comprise the normal ECM.
This process has also been shown to be active in
tumor cells as well.1,2 The pharmacologic inhibition
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of the matrix metalloproteinases (MMPs) in cancer
therapy has also been advocated as a method to
prevent or impede the invasion and metastasis
process of the tumor.2 The known role of the MMPs
and their inhibitors, the tissue inhibitor of matrix
metalloproteinases (TIMPs), in tumor metastasis
has recently been reviewed.3
In lung cancer, most of the reported studies have
been on histological specimens taken from biopsy
or surgical resection, and includes both non-small-
cell lung cancer (NSCLC) and small-cell lung cancer
(SCLC). These reports suggest that over-expression
of the metalloproteinases is a common occurrence
in lung cancer cells in vitro and may play a pivotal
role in the spread of the tumor.4–8 When a major
MMP, MMP-9, was examined in tissue culture and
conjointly up-regulated by the epidermal growth
factor receptor, the results indicated a poor
prognosis in patients with NSCLC.7
Much less is known about either circulating MMPs
or the TIMPs in those patients with lung cancer.
Thus we have elected to determine serum MMP-9
and its inhibitor, TIMP-1 in our patients with either
advanced SCLC or NSCLC before any treatment
modality and then compared to normal controls.
Patients and methods
Patients
Adult patients of both genders with pathologically
verified lung cancer, either small-cell or non-small-
cell, who were admitted to this study, were seen at
the Thoracic Oncology Clinic at the Southwest
Cancer Center. Following informed consent, a Texas
Tech Health Science Center Institutional Review
Board for Human Subjects approved study, and
prior to any treatment modality, baseline serum
samples were obtained from each patient. In all, 17
patients with either stage III or IV SCLC and 31
patients with stage III or IV NSCLC were enrolled.
All lung cancer patients had a history of smoking. In
addition, 117 normal adult non-smoking volunteers
of both sexes, greater that 40 years of age, and all
involved in health care provision had blood col-
lected to serve as the normal controls. The
demographic characteristics of the lung cancer
patients are summarized in Table 1.
Analysis
The serum content of both circulating MMP-9 and
TIMP-1 were determined by a monoclonal antibody
based sandwich ELISA utilizing commercially avail-
able kits obtained from R&D Systems, Minneapolis,
MN.
Statistics
The data was analyzed by several methodologies
utilizing the INSTAT program from Graph Pad, San
Diego CA. As patients with cancer cannot be
expected to follow the normal distribution curve,
non-parametric testing was utilized. When lung
cancer patients were compared to the controls, or
the SCLC to the NSCLC patients, the non-para-
metric Mann–Whitney t-test was used. Individual
patient relationships between MMP-9 and TIMP-1 in
each group of lung cancer patients were deter-
mined by non-parametric correlation analysis
(Spearmans correlation), while Pearson’s para-
metric linear correlation was used in the controls.
All significance levels were at the Po0:05 or
greater for two-tailed tests.
Results
To evaluate whether gender would skew the data in
the lung cancer patients, this aspect was broken
down by tumor histology as is evidenced in Table 2.
There was no significant difference in MMP-9 or
TIMP-1 when males were compared to females in
either SCLC or NSCLC. However, both male and
female patients with either SCLC or NSCLC had
significantly elevated MMP-9 and TIMP-1 when
compared to the controls.
To further evaluate any possible relationships
between MMP-9 and TIMP-1 by gender and histol-
ogy, correlation analysis was also performed. The
respective P values of these comparisons were SCLC
males 0.9, SCLC females 0.4, NSCLC males 0.8, and
NSCLC females 0.08. Therefore, the highly signifi-
cant relationship in the control patients between
MMP-9 and TIMP-1 (0.01) is lost in both the gender
and cell type examination.
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Table 1 Demographic results for the patients with
either SCLC or NSCLC.
SCLC NSCLC
N 17 31
Mean age (years) 51.6 58.2
Males 11 20
Females 6 11
Stage III 9 12
Stage IV 8 19
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As the resultant data from Table 2 indicated no
difference between SCLC and NSCLC for either
MMP-9 or TIMP-1 according to the sex of the
patient, the results were then re-examined by
stage of the tumor; which is detailed in Table 3.
As can be seen, when compared to the controls,
with the exception of MMP-9 in stage III disease, the
mean values were significantly higher than the
controls in stage III TIMP-1, and stage IV for both
MMP-9 and TIMP-1. Again there was no correlation
between MMP-9 and TIMP-1 in either stage III or
stage IV. The mean MMP-9 in stage IV lung cancer
was markedly elevated over that of stage III. Also,
the values for stage IV were uniformly greater than
those found in stage III.
As there was no significant difference between
the means of MMP-9 or TIMP-1 by gender, the data
were combined and examined by tumor histology
regardless of the stage. The combined gender mean
values for both MMP-9 and TIMP-1 in the patients
with either SCLC or NSCLC can be seen in Table 4.
Compared to the controls, both SCLC and NSCLC
induced a statistically significant increase in the
mean for both MMP-9 and TIMP-1. There was no
difference however in the means of either MMP-9 or
TIMP-1 in SCLC vs. that of NSCLC.
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Table 2 Comparison of MMP-9 and TIMP-1 in patients with either SCLC or NSCLC by gender.
Males Females Controls
SCLC, n 11 6 117
MMM-9 7907500 (0.8) 8397774 4607212
P vs. controls 0.0001 0.0001
Range 286–1657 78–1888
TIMP-1 208793 (0.2) 162744 131731
P vs. controls 0.0001 0.009
Range 111–377 105–227
NSCLC, n 20 11
MMP-9 9457597 (0.3) 7577438
p vs. controls 0.0001 0.0001
p vs. SCLC MMP-9 0.0001 0.8
Range 115–2166 300–1653
TIMP-1 2437111 (0.4) 2077100
p vs. controls 0.0001 0.0001
P vs. SCLC TIMP-1 0.3 0.2
Range 113–2166 98–385
Mean7SD, ng/mL (P between males and females).
Table 3 Comparison of MMP-9 and TIMP-1 in those patients where the SCLC and NSCLC values were combined
and then evaluated by stage of disease.
MMP-9 TIMP-1
Controls, n 117 4607212 131731
Stage III, n 21 5667430 215788
P vs. controls 0.2 0.0001
P of the correlation analysis of MMP-9 vs. TIMP-1 0.09
Stage IV, n 27 10927509 221791
P vs. controls 0.0001 0.0001
P of the correlation analysis of MMP-9 vs. TIMP-1 0.9
P of Stage III vs. Stage IV 0.0001 0.9
Mean7SD, ng/ml.
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Table 5 reflects the examination of the data
when all the SCLC and NSCLC results were
combined together without regard to gender or
stage. Both MMP-9 and TIMP-1 were again extre-
mely elevated compared to the controls.
Discussion
Lung cancer is the leading cause of cancer
mortality in the world and has a very poor
prognosis. As uPA has been suggested to up-
regulate, the MMPs have been directly linked to
the process of tumor invasion and metastasis,9 the
role of this family of enzymes and their inhibitors in
this context has received a lot of interest recently.
Resected stage I–III tissue from NSCLC patients
using immunohistochemical methods was under-
taken retrospectively.10 High tumor cell expression
of MMP-9 indicated a poorer outcome, which
suggested potentially prognostic information and
the need for development of MMP inhibitors for
cancer therapy. Further examination of lung ade-
nocarcinoma found that both MMP-3 and MMP-10
were expressed in close proximity to the area of
the ECM adjacent to the tumor blood vessels, which
should aid in angiogenesis. It was also noted that
expression of MMP-9 might be associated with in
situ tumor progression, invasion at the microvas-
cular level, as well as metastasis.11
Several studies investigating the circulating
levels of the MMPs and/or TIMPs have recently
appeared as well. A small study,12 with 19 patients
with both small-cell and NSCLC and 23 controls
found elevated MMP-9 in the serum compared to
the controls. We also noted this elevation in a much
larger population (Table 4). They also reported that
the MMP-9 levels were 3.6 times higher in the
cancer patients compared to controls while we saw
an approximate doubling for both MMP-9 and TIMP-
1. However, they did not consider this large
increase a reflection of MMP-9 over-production by
the tumor cells, yet did not offer any suggestion as
to where the MMP-9 originated. We feel that
perhaps as Kwaan has suggested,9 the circulating
uPA is activating the MMPs found in the ECM,
resulting in the release of the MMPs into the
circulation during this ECM breakdown process.
Stage II NSCLC was investigated in 44 patients
and a significant elevation was noted in MMP-1, 2,
9, and TIMP-1 and 2.13 This is in agreement with our
findings in both advanced NSCLC and SCLC. These
authors also reported the co-expression of these
factors is significant. We did not find this to be true
when comparing the statistical correlation of MMP-
9 to TIMP-1 in our patients, which was not
associated.
When 90 lung cancer patients with either
squamous cell or stage III NSCLC were compared
to 20 controls, TIMP-1 levels were elevated in the
sera of the cancer patients, and the extremely high
TIMP-1 indicated a poor prognosis.14 Likewise, high
MMP-9 was also indicative of a less than 1-year
survival potential. These authors also suggested
that both MMP-9 and TIMP-1 might be of value in
monitoring various treatment modalities. We are
currently evaluating this aspect.
The data arising from our study with a much
larger control population and including both small-
cell and NSCLC adds weight to the evidence that
both circulating MMP-9 and TIMP-1 are elevated in
these patients. As no mean significant difference
was found between the two histological types of
tumor for either MMP-9 or TIMP-1, yet both were
extremely elevated over control values, it suggests
that both tumors equally reflect the pathological
changes occurring in the tumor in respect to MMP-9
and TIMP-1. The lack of correlation observed
between MMP-9 and TIMP-1 in both SCLC and NSCLC
patients suggest that the mechanisms that maintain
homeostatic balance between activator and inhi-
bitor, as seen in the controls, is lost. This would
have a significant impact on the potential for
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Table 5 Combined levels of MMP-9 and TIMP-1 in
the patients with SCLC and NSCLC prior to treat-
ment.
MMP-9 TIMP-1
Controls, n ¼ 117 4607212 131731
Combined, n ¼ 48 878751 2197100
Po 0.0001 0.0001
Mean7SD, ng/ml.
Table 4 Levels of MMP-9 and TIMP-1 in the
patients with advanced SCLC or NSCLC regardless
of gender or stage prior to any treatment.
MMP-9 TIMP-1
Controls, n ¼ 117 4607212 131731
SCLC, n ¼ 17 8627620 200783
Po 0.01 0.0008
NSCLC, n ¼ 31 8877553 2297108
Po 0.0001 0.0001
P of SCC vs. NSCLC 0.7 0.4
Mean7SD, ng/ml.
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invasion and metastasis in the cancer patient, via
uncontrolled ECM breakdown. As both MMP-9 and
TIMP-1 increased, it would suggest that the
patients with lung cancer are trying to inhibit the
increased activity of the protease via increased
secretion of TIMP-1. This inhibition is apparently
ineffective due to the aggressive invasive nature of
these tumors. The independent action of these two
factors (loss of regulation), might also be reflective
of the large deviation seen, as some patients were
near the norm and others extremely elevated. In
our patients, 38% had elevated MMP-9, and 54% had
elevated TIMP-1. This would further tend to
support the suggestion that evaluation of circulat-
ing MMP-9 and TIMP-1 might indicate those patients
at greater risk or who might have a poorer
prognosis.
It is apparent that both MMP-9 and TIMP-1 in the
serum of patients with either SCLC or NSCLC are
reflective of the pathological changes that are
occurring in the lung. It is now time to examine
these factors in all stages of the disease, as well as
before and following palliative treatment to assess
both morbidity and mortality rates.
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